Exact Mass: 744.5176062

Argiopinin II

C35H60N12O6 (744.475854)

PG(16:1(9Z)/18:2(9Z,12Z))

C40H73O10P (744.4941087999999)

PG(16:1(9Z)/18:2(9Z,12Z)) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(16:1(9Z)/18:2(9Z,12Z)), in particular, consists of one chain of palmitoleic acid at the C-1 position and one chain of linoleic acid at the C-2 position. The palmitoleic acid moiety is derived from animal fats and vegetable oils, while the linoleic acid moiety is derived from seed oils. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PGs have a net charge of -1 at physiological pH and are found in high concentration in mitochondrial membranes and as components of pulmonary surfactant. PG also serves as a precursor for the synthesis of cardiolipin. PG is synthesized from CDP-diacylglycerol and glycerol-3-phosphate. PG(16:1(9Z)/18:2(9Z,12Z)) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(16:1(9Z)/18:2(9Z,12Z)), in particular, consists of one chain of palmitoleic acid at the C-1 position and one chain of linoleic acid at the C-2 position. The palmitoleic acid moiety is derived from animal fats and vegetable oils, while the linoleic acid moiety is derived from seed oils. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases.

PG(18:3(9Z,12Z,15Z)/16:0)

C40H73O10P (744.4941087999999)

PG(18:3(9Z,12Z,15Z)/16:0) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(18:3(9Z,12Z,15Z)/16:0), in particular, consists of one chain of a-linolenic acid at the C-1 position and one chain of palmitic acid at the C-2 position. The a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil, while the palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PGs have a net charge of -1 at physiological pH and are found in high concentration in mitochondrial membranes and as components of pulmonary surfactant. PG also serves as a precursor for the synthesis of cardiolipin. PG is synthesized from CDP-diacylglycerol and glycerol-3-phosphate. PG(18:3(9Z,12Z,15Z)/16:0) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(18:3(9Z,12Z,15Z)/16:0), in particular, consists of one chain of a-linolenic acid at the C-1 position and one chain of palmitic acid at the C-2 position. The a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil, while the palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases.

PG(16:0/18:3(6Z,9Z,12Z))

C40H73O10P (744.4941087999999)

PG(16:0/18:3(6Z,9Z,12Z)) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(16:0/18:3(6Z,9Z,12Z)), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of g-linolenic acid at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the g-linolenic acid moiety is derived from animal fats. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PGs have a net charge of -1 at physiological pH and are found in high concentration in mitochondrial membranes and as components of pulmonary surfactant. PG also serves as a precursor for the synthesis of cardiolipin. PG is synthesized from CDP-diacylglycerol and glycerol-3-phosphate. PG(16:0/18:3(6Z,9Z,12Z)) is a phosphatidylglycerol. Phosphatidylglycerols consist of a glycerol 3-phosphate backbone esterified to either saturated or unsaturated fatty acids on carbons 1 and 2. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. PG(16:0/18:3(6Z,9Z,12Z)), in particular, consists of one hexadecanoyl chain to the C-1 atom, and one 6Z,9Z,12Z-octadecatrienoyl to the C-2 atom. In E. coli glycerophospholipid metabolism, phosphatidylglycerol is formed from phosphatidic acid (1,2-diacyl-sn-glycerol 3-phosphate) by a sequence of enzymatic reactions that proceeds via two intermediates, cytidine diphosphate diacylglycerol (CDP-diacylglycerol) and phosphatidylglycerophosphate (PGP, a phosphorylated phosphatidylglycerol). Phosphatidylglycerols, along with CDP-diacylglycerol, also serve as precursor molecules for the synthesis of cardiolipin, a phospholipid found in membranes.

PG(16:0/18:3(9Z,12Z,15Z))

C40H73O10P (744.4941087999999)

PG(16:0/18:3(9Z,12Z,15Z)) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(16:0/18:3(9Z,12Z,15Z)), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of a-linolenic acid at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PGs have a net charge of -1 at physiological pH and are found in high concentration in mitochondrial membranes and as components of pulmonary surfactant. PG also serves as a precursor for the synthesis of cardiolipin. PG is synthesized from CDP-diacylglycerol and glycerol-3-phosphate. PG(16:0/18:3(9Z,12Z,15Z)) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(16:0/18:3(9Z,12Z,15Z)), in particular, consists of one chain of palmitic acid at the C-1 position and one chain of a-linolenic acid at the C-2 position. The palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats, while the a-linolenic acid moiety is derived from seed oils, especially canola and soybean oil. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases.

PG(18:2(9Z,12Z)/16:1(9Z))

C40H73O10P (744.4941087999999)

PG(18:2(9Z,12Z)/16:1(9Z)) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(18:2(9Z,12Z)/16:1(9Z)), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of palmitoleic acid at the C-2 position. The linoleic acid moiety is derived from seed oils, while the palmitoleic acid moiety is derived from animal fats and vegetable oils. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PGs have a net charge of -1 at physiological pH and are found in high concentration in mitochondrial membranes and as components of pulmonary surfactant. PG also serves as a precursor for the synthesis of cardiolipin. PG is synthesized from CDP-diacylglycerol and glycerol-3-phosphate. PG(18:2(9Z,12Z)/16:1(9Z)) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(18:2(9Z,12Z)/16:1(9Z)), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of palmitoleic acid at the C-2 position. The linoleic acid moiety is derived from seed oils, while the palmitoleic acid moiety is derived from animal fats and vegetable oils. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases.

PG(18:3(6Z,9Z,12Z)/16:0)

C40H73O10P (744.4941087999999)

PG(18:3(6Z,9Z,12Z)/16:0) is a phosphatidylglycerol or glycerophospholipid (PG or GP). It is a glycerophospholipid in which a phosphoglycerol moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PG(18:3(6Z,9Z,12Z)/16:0), in particular, consists of one chain of g-linolenic acid at the C-1 position and one chain of palmitic acid at the C-2 position. The g-linolenic acid moiety is derived from animal fats, while the palmitic acid moiety is derived from fish oils, milk fats, vegetable oils and animal fats. Phosphatidylglycerol is present at a level of 1-2\\% in most animal tissues, but it can be the second most abundant phospholipid in lung surfactant at up to 11\\% of the total. It is well established that the concentration of phosphatidylglycerol increases during fetal development. Phosphatidylglycerol may be present in animal tissues merely as a precursor for diphosphatidylglycerol (cardiolipin). Phosphatidylglycerol is formed from phosphatidic acid by a sequence of enzymatic reactions that proceeds via the intermediate, cytidine diphosphate diacylglycerol (CDP-diacylglycerol). Bioynthesis proceeds by condensation of phosphatidic acid and cytidine triphosphate with elimination of pyrophosphate via the action of phosphatidate cytidyltransferase (or CDP-synthase). CDP-diacylglycerol then reacts with glycerol-3-phosphate via phosphatidylglycerophosphate synthase to form 3-sn-phosphatidyl-1-sn-glycerol 3-phosphoric acid, with the release of cytidine monophosphate (CMP). Finally, phosphatidylglycerol is formed by the action of specific phosphatases. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PGs have a net charge of -1 at physiological pH and are found in high concentration in mitochondrial membranes and as components of pulmonary surfactant. PG also serves as a precursor for the synthesis of cardiolipin. PG is synthesized from CDP-diacylglycerol and glycerol-3-phosphate. PG(18:3(6Z,9Z,12Z)/16:0) is a phosphatidylglycerol. Phosphatidylglycerols consist of a glycerol 3-phosphate backbone esterified to either saturated or unsaturated fatty acids on carbons 1 and 2. As is the case with diacylglycerols, phosphatidylglycerols can have many different combinations of fatty acids of varying lengths and saturation attached to the C-1 and C-2 positions. PG(18:3(6Z,9Z,12Z)/16:0), in particular, consists of one 6Z,9Z,12Z-octadecatrienoyl chain to the C-1 atom, and one hexadecanoyl to the C-2 atom. In E. coli glycerophospholipid metabolism, phosphatidylglycerol is formed from phosphatidic acid (1,2-diacyl-sn-glycerol 3-phosphate) by a sequence of enzymatic reactions that proceeds via two intermediates, cytidine diphosphate diacylglycerol (CDP-diacylglycerol) and phosphatidylglycerophosphate (PGP, a phosphorylated phosphatidylglycerol). Phosphatidylglycerols, along with CDP-diacylglycerol, also serve as precursor molecules for the synthesis of cardiolipin, a phospholipid found in membranes.

PA(15:0/24:1(15Z))

C42H81O8P (744.5668756)

PA(15:0/24:1(15Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(15:0/24:1(15Z)), in particular, consists of one chain of pentadecanoic acid at the C-1 position and one chain of nervonic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

C43H69O8P (744.4729804)

PA(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of linoleic acid at the C-1 position and one chain of docosahexaenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z))

C43H69O8P (744.4729804)

PA(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:3(6Z,9Z,12Z)/22:5(4Z,7Z,10Z,13Z,16Z)), in particular, consists of one chain of gamma-linolenic acid at the C-1 position and one chain of osbond acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z))

C43H69O8P (744.4729804)

PA(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:3(6Z,9Z,12Z)/22:5(7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of gamma-linolenic acid at the C-1 position and one chain of clupanodonic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z))

C43H69O8P (744.4729804)

PA(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:3(9Z,12Z,15Z)/22:5(4Z,7Z,10Z,13Z,16Z)), in particular, consists of one chain of alpha-linolenic acid at the C-1 position and one chain of osbond acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z))

C43H69O8P (744.4729804)

PA(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:3(9Z,12Z,15Z)/22:5(7Z,10Z,13Z,16Z,19Z)), in particular, consists of one chain of alpha-linolenic acid at the C-1 position and one chain of clupanodonic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))

C43H69O8P (744.4729804)

PA(18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z)), in particular, consists of one chain of stearidonic acid at the C-1 position and one chain of adrenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z))

C43H69O8P (744.4729804)

PA(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:3(5Z,8Z,11Z)/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of mead acid at the C-1 position and one chain of eicosapentaenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))

C43H69O8P (744.4729804)

PA(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of arachidonic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z))

C43H69O8P (744.4729804)

PA(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:4(5Z,8Z,11Z,14Z)/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of eicosatetraenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z))

C43H69O8P (744.4729804)

PA(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:4(8Z,11Z,14Z,17Z)/20:4(5Z,8Z,11Z,14Z)), in particular, consists of one chain of eicosatetraenoic acid at the C-1 position and one chain of arachidonic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z))

C43H69O8P (744.4729804)

PA(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:4(8Z,11Z,14Z,17Z)/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of eicosatetraenoic acid at the C-1 position and one chain of eicosatetraenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z))

C43H69O8P (744.4729804)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(5Z,8Z,11Z)), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position and one chain of mead acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))

C43H69O8P (744.4729804)

PA(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z)), in particular, consists of one chain of adrenic acid at the C-1 position and one chain of stearidonic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z))

C43H69O8P (744.4729804)

PA(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(6Z,9Z,12Z)), in particular, consists of one chain of osbond acid at the C-1 position and one chain of gamma-linolenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z))

C43H69O8P (744.4729804)

PA(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:5(4Z,7Z,10Z,13Z,16Z)/18:3(9Z,12Z,15Z)), in particular, consists of one chain of osbond acid at the C-1 position and one chain of alpha-linolenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z))

C43H69O8P (744.4729804)

PA(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(6Z,9Z,12Z)), in particular, consists of one chain of clupanodonic acid at the C-1 position and one chain of gamma-linolenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z))

C43H69O8P (744.4729804)

PA(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:5(7Z,10Z,13Z,16Z,19Z)/18:3(9Z,12Z,15Z)), in particular, consists of one chain of clupanodonic acid at the C-1 position and one chain of alpha-linolenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))

C43H69O8P (744.4729804)

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z)), in particular, consists of one chain of docosahexaenoic acid at the C-1 position and one chain of linoleic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(24:1(15Z)/15:0)

C42H81O8P (744.5668756)

PA(24:1(15Z)/15:0) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(24:1(15Z)/15:0), in particular, consists of one chain of nervonic acid at the C-1 position and one chain of pentadecanoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(20:3(8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))

C43H69O8P (744.4729804)

PA(20:3(8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:3(8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z)), in particular, consists of one chain of dihomo-gamma-linolenic acid at the C-1 position and one chain of eicosapentaenoic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z))

C43H69O8P (744.4729804)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z)) is a phosphatidic acid. It is a glycerophospholipid in which a phosphate moiety occupies a glycerol substitution site. As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z)), in particular, consists of one chain of eicosapentaenoic acid at the C-1 position and one chain of dihomo-gamma-linolenic acid at the C-2 position. Phosphatidic acids are quite rare but are extremely important as intermediates in the biosynthesis of triacylglycerols and phospholipids.

Lipofectin

C41H77O9P (744.5304922)

PA(17:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C40H73O10P (744.4941087999999)

PA(17:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(17:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one heptadecanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/17:0)

C40H73O10P (744.4941087999999)

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/17:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/17:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of heptadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(19:2(10Z,13Z)/18:1(12Z)-2OH(9,10))

C40H73O10P (744.4941087999999)

PA(19:2(10Z,13Z)/18:1(12Z)-2OH(9,10)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(19:2(10Z,13Z)/18:1(12Z)-2OH(9,10)), in particular, consists of one chain of one 10Z,13Z-nonadecadienoyl at the C-1 position and one chain of 9,10-hydroxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:1(12Z)-2OH(9,10)/19:2(10Z,13Z))

C40H73O10P (744.4941087999999)

PA(18:1(12Z)-2OH(9,10)/19:2(10Z,13Z)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-2OH(9,10)/19:2(10Z,13Z)), in particular, consists of one chain of one 9,10-hydroxy-octadecenoyl at the C-1 position and one chain of 10Z,13Z-nonadecadienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:0/18:1(12Z)-O(9S,10R))

C41H77O9P (744.5304922)

PA(20:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one eicosanoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:1(12Z)-O(9S,10R)/20:0)

C41H77O9P (744.5304922)

PA(18:1(12Z)-O(9S,10R)/20:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-O(9S,10R)/20:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of eicosanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:0/18:1(9Z)-O(12,13))

C41H77O9P (744.5304922)

PA(20:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one eicosanoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:1(9Z)-O(12,13)/20:0)

C41H77O9P (744.5304922)

PA(18:1(9Z)-O(12,13)/20:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(9Z)-O(12,13)/20:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of eicosanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(a-17:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C40H73O10P (744.4941087999999)

PA(a-17:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(a-17:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one 14-methylhexadecanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/a-17:0)

C40H73O10P (744.4941087999999)

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/a-17:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/a-17:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of 14-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-17:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C40H73O10P (744.4941087999999)

PA(i-17:0/20:3(8Z,11Z,14Z)-2OH(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-17:0/20:3(8Z,11Z,14Z)-2OH(5,6)), in particular, consists of one chain of one 15-methylhexadecanoyl at the C-1 position and one chain of 5,6-dihydroxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-17:0)

C40H73O10P (744.4941087999999)

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-17:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-17:0), in particular, consists of one chain of one 5,6-dihydroxyeicosatrienoyl at the C-1 position and one chain of 15-methylhexadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-20:0/18:1(12Z)-O(9S,10R))

C41H77O9P (744.5304922)

PA(i-20:0/18:1(12Z)-O(9S,10R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-20:0/18:1(12Z)-O(9S,10R)), in particular, consists of one chain of one 18-methylnonadecanoyl at the C-1 position and one chain of 9,10-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:1(12Z)-O(9S,10R)/i-20:0)

C41H77O9P (744.5304922)

PA(18:1(12Z)-O(9S,10R)/i-20:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(12Z)-O(9S,10R)/i-20:0), in particular, consists of one chain of one 9,10-epoxy-octadecenoyl at the C-1 position and one chain of 18-methylnonadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(i-20:0/18:1(9Z)-O(12,13))

C41H77O9P (744.5304922)

PA(i-20:0/18:1(9Z)-O(12,13)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(i-20:0/18:1(9Z)-O(12,13)), in particular, consists of one chain of one 18-methylnonadecanoyl at the C-1 position and one chain of 12,13-epoxy-octadecenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

PA(18:1(9Z)-O(12,13)/i-20:0)

C41H77O9P (744.5304922)

PA(18:1(9Z)-O(12,13)/i-20:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(18:1(9Z)-O(12,13)/i-20:0), in particular, consists of one chain of one 12,13-epoxy-octadecenoyl at the C-1 position and one chain of 18-methylnonadecanoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

SM(d16:1/5-iso PGF2VI)

C39H73N2O9P (744.5053418)

SM(d16:1/5-iso PGF2VI) is a type of oxidized sphingolipid found in animal cell membranes. It usually consists of phosphorylcholine and ceramide. SM(d16:1/5-iso PGF2VI) consists of a sphingosine backbone and a 5-iso Prostaglandin F2alpha-VI chain. In humans, sphingomyelin is the only membrane phospholipid not derived from glycerol. Like all sphingolipids, SM has a ceramide core (sphingosine bonded to a fatty acid via an amide linkage). In addition, it contains one polar head group, which is either phosphocholine or phosphoethanolamine. The plasma membrane of cells is highly enriched in sphingomyelin and is considered largely to be found in the exoplasmic leaflet of the cell membrane. However, there is some evidence that there may also be a sphingomyelin pool in the inner leaflet of the membrane. Moreover, neutral sphingomyelinase-2, an enzyme that breaks down sphingomyelin into ceramide, has been found to localize exclusively to the inner leaflet further suggesting that there may be sphingomyelin present there. Sphingomyelin can accumulate in a rare hereditary disease called Niemann-Pick Disease, types A and B. Niemann-Pick disease is a genetically-inherited disease caused by a deficiency in the enzyme sphingomyelinase, which causes the accumulation of sphingomyelin in spleen, liver, lungs, bone marrow, and the brain, causing irreversible neurological damage. SMs play a role in signal transduction. Sphingomyelins are synthesized by the transfer of phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by sphingomyelin synthase.

SM(d17:2(4E,8Z)/18:1(12Z)-2OH(9,10))

C40H77N2O8P (744.5417252000001)

SM(d17:2(4E,8Z)/18:1(12Z)-2OH(9,10)) is a type of oxidized sphingolipid found in animal cell membranes. It usually consists of phosphorylcholine and ceramide. SM(d17:2(4E,8Z)/18:1(12Z)-2OH(9,10)) consists of a sphingosine backbone and a 9,10-hydroxy-octadecenoyl chain. In humans, sphingomyelin is the only membrane phospholipid not derived from glycerol. Like all sphingolipids, SM has a ceramide core (sphingosine bonded to a fatty acid via an amide linkage). In addition, it contains one polar head group, which is either phosphocholine or phosphoethanolamine. The plasma membrane of cells is highly enriched in sphingomyelin and is considered largely to be found in the exoplasmic leaflet of the cell membrane. However, there is some evidence that there may also be a sphingomyelin pool in the inner leaflet of the membrane. Moreover, neutral sphingomyelinase-2, an enzyme that breaks down sphingomyelin into ceramide, has been found to localize exclusively to the inner leaflet further suggesting that there may be sphingomyelin present there. Sphingomyelin can accumulate in a rare hereditary disease called Niemann-Pick Disease, types A and B. Niemann-Pick disease is a genetically-inherited disease caused by a deficiency in the enzyme sphingomyelinase, which causes the accumulation of sphingomyelin in spleen, liver, lungs, bone marrow, and the brain, causing irreversible neurological damage. SMs play a role in signal transduction. Sphingomyelins are synthesized by the transfer of phosphorylcholine from phosphatidylcholine to a ceramide in a reaction catalyzed by sphingomyelin synthase.

1-18:3-2-16:4-monogalactosyldiacylglycerol

C43H68O10 (744.4812228000001)

Tetraacetyl-beta-sitosterylglucosid

C43H68O10 (744.4812228000001)

Raspailamide A

C42H68N2O9 (744.4924558000001)

argentinic acid D methyl ester

C43H68O10 (744.4812228000001)

myxol-2-O-methyl methylpentoside

C47H68O7 (744.4964778000001)

myxol-2-O-methyl-alpha-fucoside

C47H68O7 (744.4964778000001)

1-linoleoyl-2-(3E)-hexadecenoyl-phosphatidylglycerol

C40H73O10P (744.4941087999999)

16:0 PG (1,2-dihexadecanoyl-sn-glycero-3-phospho-(1-rac-glycerol) (sodium salt))

C38H74NaO10P (744.4917034)

PG 34:3

C40H73O10P (744.4941087999999)

Found in mouse lung; TwoDicalId=482; MgfFile=160901_Lung_EPA_Neg_07; MgfId=428 Found in mouse spleen; TwoDicalId=1266; MgfFile=160729_spleen_normal_01_Neg; MgfId=498

PG(34:3)

C40H73O10P (744.4941087999999)

PG(14:0/20:3(8Z,11Z,14Z))

C40H73O10P (744.4941087999999)

PG(14:1(9Z)/20:2(11Z,14Z))

C40H73O10P (744.4941087999999)

PG(17:1(9Z)/17:2(9Z,12Z))

C40H73O10P (744.4941087999999)

PG(17:2(9Z,12Z)/17:1(9Z))

C40H73O10P (744.4941087999999)

PG(20:2(11Z,14Z)/14:1(9Z))

C40H73O10P (744.4941087999999)

PG(20:3(8Z,11Z,14Z)/14:0)

C40H73O10P (744.4941087999999)

PG(P-18:0/17:2(9Z,12Z))

C41H77O9P (744.5304922)

PA(17:0/22:1(11Z))

C42H81O8P (744.5668756)

PA(17:1(9Z)/22:0)

C42H81O8P (744.5668756)

PA(18:1(9Z)/21:0)

C42H81O8P (744.5668756)

PA(18:4(6Z,9Z,12Z,15Z)/22:4(7Z,10Z,13Z,16Z))

C43H69O8P (744.4729804)

PA(19:0/20:1(11Z))

C42H81O8P (744.5668756)

PA(19:1(9Z)/20:0)

C42H81O8P (744.5668756)

PA(20:0/19:1(9Z))

C42H81O8P (744.5668756)

PA(20:1(11Z)/19:0)

C42H81O8P (744.5668756)

PA(20:3(8Z,11Z,14Z)/20:5(5Z,8Z,11Z,14Z,17Z))

C43H69O8P (744.4729804)

PA(20:5(5Z,8Z,11Z,14Z,17Z)/20:3(8Z,11Z,14Z))

C43H69O8P (744.4729804)

PA(21:0/18:1(9Z))

C42H81O8P (744.5668756)

PA(22:0/17:1(9Z))

C42H81O8P (744.5668756)

PA(22:1(11Z)/17:0)

C42H81O8P (744.5668756)

PA(22:4(7Z,10Z,13Z,16Z)/18:4(6Z,9Z,12Z,15Z))

C43H69O8P (744.4729804)

PA(22:6(4Z,7Z,10Z,13Z,16Z,19Z)/18:2(9Z,12Z))

C43H69O8P (744.4729804)

PA(20:4(5Z,8Z,11Z,14Z)/20:4(5Z,8Z,11Z,14Z))

C43H69O8P (744.4729804)

PA(18:2(9Z,12Z)/22:6(4Z,7Z,10Z,13Z,16Z,19Z))

C43H69O8P (744.4729804)

MGDG 34:7

C43H68O10 (744.4812228000001)

PG O-35:3

C41H77O9P (744.5304922)

PA 39:1

C42H81O8P (744.5668756)

PA 40:8

C43H69O8P (744.4729804)

Myxol 2-dimethyl pentoside

C47H68O7 (744.4964778000001)

Myxol 2-O-methyl-methylpentoside

C47H68O7 (744.4964778000001)

dibutylbis(palmitoyloxy)stannane

C40H80O4Sn (744.507827)

Glycine,N-methyl-N-[(9Z)-1-oxo-9-octadecen-1-yl]-, calcium salt (2:1)

C42H76CaN2O6 (744.5328986)

Bis(lauroyloxy)dioctyltin

C40H80O4Sn (744.507827)

2,3,6,7,10,11-HEXAKIS(PENTYLOXY)TRIPHENYLENE

C48H72O6 (744.5328612000001)

Lipofectin

C41H77O9P (744.5304922)

1,2-Dipalmitoyl-sn-glycero-3-phospho-(1-rac-glycerol), sodium salt

C38H74NaO10P (744.4917034)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C40H73O10P (744.4941087999999)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-hexadec-3-enoyl]oxypropyl] (9Z,12Z)-octadeca-9,12-dienoate

C40H73O10P (744.4941087999999)

[(2Z,6E,10E)-3,7,11,15,19,23,27-heptamethyloctacosa-2,6,10-trienyl] [(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] hydrogen phosphate

C41H77O9P (744.5304922)

PA(20:0/18:1(12Z)-O(9S,10R))

C41H77O9P (744.5304922)

PA(18:1(12Z)-O(9S,10R)/20:0)

C41H77O9P (744.5304922)

PA(i-20:0/18:1(12Z)-O(9S,10R))

C41H77O9P (744.5304922)

PA(18:1(12Z)-O(9S,10R)/i-20:0)

C41H77O9P (744.5304922)

PA(i-20:0/18:1(9Z)-O(12,13))

C41H77O9P (744.5304922)

PA(18:1(9Z)-O(12,13)/i-20:0)

C41H77O9P (744.5304922)

[(2R)-2-[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy-3-phosphonooxypropyl] icosanoate

C41H77O9P (744.5304922)

[(2R)-1-[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy-3-phosphonooxypropan-2-yl] icosanoate

C41H77O9P (744.5304922)

PA(17:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C40H73O10P (744.4941087999999)

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/17:0)

C40H73O10P (744.4941087999999)

PA(a-17:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C40H73O10P (744.4941087999999)

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/a-17:0)

C40H73O10P (744.4941087999999)

PA(i-17:0/20:3(8Z,11Z,14Z)-2OH(5,6))

C40H73O10P (744.4941087999999)

PA(20:3(8Z,11Z,14Z)-2OH(5,6)/i-17:0)

C40H73O10P (744.4941087999999)

PA(19:2(10Z,13Z)/18:1(12Z)-2OH(9,10))

C40H73O10P (744.4941087999999)

PA(18:1(12Z)-2OH(9,10)/19:2(10Z,13Z))

C40H73O10P (744.4941087999999)

SM(d16:1/5-iso PGF2VI)

C39H73N2O9P (744.5053418)

SM(d17:2(4E,8Z)/18:1(12Z)-2OH(9,10))

C40H77N2O8P (744.5417252000001)

2-[hydroxy-[(2R)-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-pentadecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-3-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-2-pentadecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-2-[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy-3-tetradecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C40H75NO9P+ (744.517917)

2-[hydroxy-[(2R)-3-[(10E,12Z)-9-oxooctadeca-10,12-dienoyl]oxy-2-tetradecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C40H75NO9P+ (744.517917)

2-[hydroxy-[(2R)-2-[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy-3-tetradecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C40H75NO9P+ (744.517917)

2-[hydroxy-[(2R)-3-[(9Z,11E)-13-oxooctadeca-9,11-dienoyl]oxy-2-tetradecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C40H75NO9P+ (744.517917)

2-[hydroxy-[(2R)-2-[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy-3-tetradecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C40H75NO9P+ (744.517917)

2-[hydroxy-[(2R)-3-[(10E,12E,15E)-9-hydroxyoctadeca-10,12,15-trienoyl]oxy-2-tetradecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C40H75NO9P+ (744.517917)

2-[hydroxy-[(2R)-2-[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy-3-tetradecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C40H75NO9P+ (744.517917)

2-[hydroxy-[(2R)-3-[(9E,11E,15E)-13-hydroxyoctadeca-9,11,15-trienoyl]oxy-2-tetradecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C40H75NO9P+ (744.517917)

2-[hydroxy-[(2R)-2-[8-[3-[(Z)-oct-2-enyl]oxiran-2-yl]octanoyloxy]-3-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C40H75NO9P+ (744.517917)

2-[hydroxy-[(2R)-3-[8-[3-[(Z)-oct-2-enyl]oxiran-2-yl]octanoyloxy]-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C40H75NO9P+ (744.517917)

2-[hydroxy-[(2R)-2-[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C40H75NO9P+ (744.517917)

2-[hydroxy-[(2R)-3-[(Z)-11-(3-pentyloxiran-2-yl)undec-9-enoyl]oxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C40H75NO9P+ (744.517917)

AcChaArgTicNleNHCH2CH2Ph

C41H60N8O5 (744.4686429999999)

N-stearoyl-1-oleoyl-sn-glycero-3-phosphoethanolamine(1-)

C41H79NO8P- (744.5543004)

(2R)-2-{[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy}-3-{[(9Z)-octadec-9-enoyl]oxy}propyl phosphate

C43H69O8P-2 (744.4729804)

3-{[(2,3-dihydroxypropoxy)(hydroxy)phosphoryl]oxy}-2-(hexadecanoyloxy)propyl (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C40H73O10P (744.4941087999999)

1-linoleoyl-2-[(3E)-hexadecenoyl]-sn-glycero-3-phosphoglycerol

C40H73O10P (744.4941087999999)

A phosphatidylglycerol (18:2/16:1) in which the 1- and 2-acyl groups are specified as linoleoyl and (3E)-hexadecenoyl respectively.

2-[hydroxy-[(2R)-2-[(Z)-octadec-9-enoyl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-3-[(Z)-octadec-9-enoyl]oxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-tridecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[[(2R)-3-[(Z)-heptadec-9-enoyl]oxy-2-[(Z)-hexadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-2-[(Z)-nonadec-9-enoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[[(2R)-2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[[(2R)-2-[(Z)-heptadec-9-enoyl]oxy-3-[(Z)-hexadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[[(2R)-3-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-2-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-3-[(Z)-nonadec-9-enoyl]oxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-3-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-2-tridecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C43H68O10 (744.4812228000001)

NAGlySer 22:4/17:0

C44H76N2O7 (744.5652226)

NAGlySer 18:3/21:1

C44H76N2O7 (744.5652226)

NAGlySer 21:1/18:3

C44H76N2O7 (744.5652226)

NAGlySer 17:2/22:2

C44H76N2O7 (744.5652226)

NAGlySer 21:2/18:2

C44H76N2O7 (744.5652226)

NAGlySer 19:0/20:4

C44H76N2O7 (744.5652226)

NAGlySer 24:4/15:0

C44H76N2O7 (744.5652226)

NAGlySer 19:1/20:3

C44H76N2O7 (744.5652226)

NAGlySer 18:2/21:2

C44H76N2O7 (744.5652226)

NAGlySer 19:2/20:2

C44H76N2O7 (744.5652226)

NAGlySer 13:0/26:4

C44H76N2O7 (744.5652226)

NAGlySer 15:0/24:4

C44H76N2O7 (744.5652226)

NAGlySer 18:4/21:0

C44H76N2O7 (744.5652226)

NAGlySer 22:2/17:2

C44H76N2O7 (744.5652226)

NAGlySer 20:3/19:1

C44H76N2O7 (744.5652226)

NAGlySer 26:3/13:1

C44H76N2O7 (744.5652226)

NAGlySer 20:4/19:0

C44H76N2O7 (744.5652226)

NAGlySer 24:3/15:1

C44H76N2O7 (744.5652226)

NAGlySer 17:0/22:4

C44H76N2O7 (744.5652226)

NAGlySer 20:2/19:2

C44H76N2O7 (744.5652226)

NAGlySer 17:1/22:3

C44H76N2O7 (744.5652226)

NAGlySer 16:4/23:0

C44H76N2O7 (744.5652226)

NAGlySer 26:4/13:0

C44H76N2O7 (744.5652226)

NAGlySer 22:3/17:1

C44H76N2O7 (744.5652226)

NAOrn 22:6/20:4

C47H72N2O5 (744.5440942)

NAOrn 26:7/16:3

C47H72N2O5 (744.5440942)

NAOrn 20:5/22:5

C47H72N2O5 (744.5440942)

Mgdg O-28:7_7:0

C44H72O9 (744.5176062)

Mgdg O-26:7_9:0

C44H72O9 (744.5176062)

Mgdg O-9:0_26:7

C44H72O9 (744.5176062)

Mgdg O-17:2_18:5

C44H72O9 (744.5176062)

Mgdg O-13:1_22:6

C44H72O9 (744.5176062)

Mgdg O-18:5_17:2

C44H72O9 (744.5176062)

Mgdg O-22:6_13:1

C44H72O9 (744.5176062)

PE-Cer 15:1;2O/26:7

C43H73N2O6P (744.5205968)

PE-Cer 21:3;2O/20:5

C43H73N2O6P (744.5205968)

PE-Cer 17:3;2O/24:5

C43H73N2O6P (744.5205968)

PE-Cer 15:2;2O/26:6

C43H73N2O6P (744.5205968)

PE-Cer 19:2;2O/22:6

C43H73N2O6P (744.5205968)

PE-Cer 23:3;2O/18:5

C43H73N2O6P (744.5205968)

PE-Cer 17:2;2O/24:6

C43H73N2O6P (744.5205968)

PE-Cer 19:3;2O/22:5

C43H73N2O6P (744.5205968)

PE-Cer 15:3;2O/26:5

C43H73N2O6P (744.5205968)

[(E)-3-hydroxy-2-[[(9Z,12Z,15Z,18Z,21Z,24Z,27Z)-triaconta-9,12,15,18,21,24,27-heptaenoyl]amino]oct-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate

C43H73N2O6P (744.5205968)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-heptadeca-9,12-dienoxy]propan-2-yl] (Z)-octadec-9-enoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] (Z)-nonadec-9-enoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propan-2-yl] (Z)-pentadec-9-enoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoxy]propan-2-yl] undecanoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(13Z,16Z)-docosa-13,16-dienoxy]propan-2-yl] (Z)-tridec-9-enoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-heptadec-9-enoxy]propan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoxy]propan-2-yl] (11Z,14Z)-icosa-11,14-dienoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-nonadecoxypropan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-heptadecoxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] heptadecanoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-nonadec-9-enoxy]propan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-undecoxypropan-2-yl] (10Z,13Z,16Z)-tetracosa-10,13,16-trienoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoxy]propan-2-yl] (13Z,16Z)-docosa-13,16-dienoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propan-2-yl] (Z)-hexadec-9-enoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tridecoxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-pentadecoxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] (Z)-heptadec-9-enoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] nonadecanoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoxy]propan-2-yl] tridecanoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-octadec-9-enoxy]propan-2-yl] (9Z,12Z)-heptadeca-9,12-dienoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]propan-2-yl] pentadecanoate

C41H77O9P (744.5304922)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-henicosa-11,14-dienoxy]propan-2-yl] (Z)-tetradec-9-enoate

C41H77O9P (744.5304922)

[(E)-2-[[(5Z,8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]amino]-3-hydroxydodec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate

C43H73N2O6P (744.5205968)

[(4E,8E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoyl]amino]tetradeca-4,8-dienyl] 2-(trimethylazaniumyl)ethyl phosphate

C43H73N2O6P (744.5205968)

[(4E,8E,12E)-3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]icosa-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate

C43H73N2O6P (744.5205968)

[(4E,8E)-2-[[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoyl]amino]-3-hydroxydodeca-4,8-dienyl] 2-(trimethylazaniumyl)ethyl phosphate

C43H73N2O6P (744.5205968)

[(4E,8E,12E)-3-hydroxy-2-[[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoyl]amino]tetradeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate

C43H73N2O6P (744.5205968)

[(E)-3-hydroxy-2-[[(7Z,10Z,13Z,16Z,19Z,22Z,25Z)-octacosa-7,10,13,16,19,22,25-heptaenoyl]amino]dec-4-enyl] 2-(trimethylazaniumyl)ethyl phosphate

C43H73N2O6P (744.5205968)

[(4E,8E,12E)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]octadeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate

C43H73N2O6P (744.5205968)

[(4E,8E,12E)-2-[[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]amino]-3-hydroxyhexadeca-4,8,12-trienyl] 2-(trimethylazaniumyl)ethyl phosphate

C43H73N2O6P (744.5205968)

[(4E,8E)-2-[[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]amino]-3-hydroxyhexadeca-4,8-dienyl] 2-(trimethylazaniumyl)ethyl phosphate

C43H73N2O6P (744.5205968)

[3-nonanoyloxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropyl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C48H72O6 (744.5328612000001)

PMeOH 39:8

C43H69O8P (744.4729804)

PEtOH 21:0_16:1

C42H81O8P (744.5668756)

PMeOH 17:0_21:1

C42H81O8P (744.5668756)

PMeOH 22:0_16:1

C42H81O8P (744.5668756)

PEtOH 23:0_14:1

C42H81O8P (744.5668756)

PEtOH 18:4_20:4

C43H69O8P (744.4729804)

PMeOH 12:0_26:1

C42H81O8P (744.5668756)

PEtOH 18:3_20:5

C43H69O8P (744.4729804)

PMeOH 18:0_20:1

C42H81O8P (744.5668756)

PEtOH 16:2_22:6

C43H69O8P (744.4729804)

PEtOH 16:3_22:5

C43H69O8P (744.4729804)

PEtOH 20:0_17:1

C42H81O8P (744.5668756)

PEtOH 18:0_19:1

C42H81O8P (744.5668756)

PEtOH 19:0_18:1

C42H81O8P (744.5668756)

PEtOH 22:0_15:1

C42H81O8P (744.5668756)

PMeOH 20:0_18:1

C42H81O8P (744.5668756)

PEtOH 20:3_18:5

C43H69O8P (744.4729804)

PMeOH 14:0_24:1

C42H81O8P (744.5668756)

PEtOH 13:0_24:1

C42H81O8P (744.5668756)

PMeOH 16:0_22:1

C42H81O8P (744.5668756)

PEtOH 24:0_13:1

C42H81O8P (744.5668756)

PEtOH 16:4_22:4

C43H69O8P (744.4729804)

PEtOH 15:0_22:1

C42H81O8P (744.5668756)

PMeOH 21:0_17:1

C42H81O8P (744.5668756)

PMeOH 23:0_15:1

C42H81O8P (744.5668756)

PMeOH 19:0_19:1

C42H81O8P (744.5668756)

PEtOH 17:0_20:1

C42H81O8P (744.5668756)

PMeOH 24:0_14:1

C42H81O8P (744.5668756)

PEtOH 16:0_21:1

C42H81O8P (744.5668756)

PMeOH 25:0_13:1

C42H81O8P (744.5668756)

3,4,5-Trihydroxy-6-(3-nonadecanoyloxy-2-tridecanoyloxypropoxy)oxane-2-carboxylic acid

C41H76O11 (744.5387346)

[1-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate

C43H68O10 (744.4812228000001)

6-(3-Heptadecanoyloxy-2-pentadecanoyloxypropoxy)-3,4,5-trihydroxyoxane-2-carboxylic acid

C41H76O11 (744.5387346)

3,4,5-Trihydroxy-6-(3-octadecanoyloxy-2-tetradecanoyloxypropoxy)oxane-2-carboxylic acid

C41H76O11 (744.5387346)

6-(2-Dodecanoyloxy-3-icosanoyloxypropoxy)-3,4,5-trihydroxyoxane-2-carboxylic acid

C41H76O11 (744.5387346)

6-[2,3-Di(hexadecanoyloxy)propoxy]-3,4,5-trihydroxyoxane-2-carboxylic acid

C41H76O11 (744.5387346)

[1-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate

C43H68O10 (744.4812228000001)

[3-hydroxy-2-[[(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z)-triaconta-6,9,12,15,18,21,24,27-octaenoyl]amino]octyl] 2-(trimethylazaniumyl)ethyl phosphate

C43H73N2O6P (744.5205968)

[1-[[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-octadec-9-enoate

C40H73O10P (744.4941087999999)

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate

C40H73O10P (744.4941087999999)

[1-[[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (Z)-heptadec-9-enoate

C40H73O10P (744.4941087999999)

[1-hydroxy-3-[hydroxy-(3-hydroxy-2-tetradecanoyloxypropoxy)phosphoryl]oxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C40H73O10P (744.4941087999999)

[1-[[2-[(Z)-hexadec-9-enoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate

C40H73O10P (744.4941087999999)

[1-[[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-hydroxypropoxy]-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] octadecanoate

C40H73O10P (744.4941087999999)

[1-[(2-hexadecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C40H73O10P (744.4941087999999)

[1-[(2-dodecanoyloxy-3-hydroxypropoxy)-hydroxyphosphoryl]oxy-3-hydroxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C40H73O10P (744.4941087999999)

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

C40H73O10P (744.4941087999999)

[1-hydroxy-3-[hydroxy-[3-hydroxy-2-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate

C40H73O10P (744.4941087999999)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropan-2-yl] (9Z,12Z)-nonadeca-9,12-dienoate

C40H73O10P (744.4941087999999)

[1-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate

C43H69O8P (744.4729804)

[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxypropyl] octadecanoate

C40H73O10P (744.4941087999999)

(1-octadecanoyloxy-3-phosphonooxypropan-2-yl) (Z)-henicos-11-enoate

C42H81O8P (744.5668756)

[3-phosphonooxy-2-[(Z)-tridec-9-enoyl]oxypropyl] hexacosanoate

C42H81O8P (744.5668756)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-dodecanoyloxypropan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C40H73O10P (744.4941087999999)

[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxypropyl] (Z)-heptadec-9-enoate

C40H73O10P (744.4941087999999)

[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-phosphonooxypropyl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C43H69O8P (744.4729804)

[1-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoate

C43H69O8P (744.4729804)

[2-[(Z)-heptadec-9-enoyl]oxy-3-phosphonooxypropyl] docosanoate

C42H81O8P (744.5668756)

(1-nonadecanoyloxy-3-phosphonooxypropan-2-yl) (Z)-icos-11-enoate

C42H81O8P (744.5668756)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate

C40H73O10P (744.4941087999999)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropan-2-yl] (11Z,14Z)-icosa-11,14-dienoate

C40H73O10P (744.4941087999999)

[1-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate

C43H69O8P (744.4729804)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate

C40H73O10P (744.4941087999999)

[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-phosphonooxypropyl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate

C43H69O8P (744.4729804)

[3-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxypropyl] (Z)-octadec-9-enoate

C40H73O10P (744.4941087999999)

[1-[2,3-dihydroxypropoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tridec-9-enoyl]oxypropan-2-yl] (11Z,14Z)-henicosa-11,14-dienoate

C40H73O10P (744.4941087999999)

[1-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxy-3-phosphonooxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate

C43H69O8P (744.4729804)

[2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-3-phosphonooxypropyl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate

C43H69O8P (744.4729804)

2-[hydroxy-[(2R)-3-[(E)-octadec-9-enoyl]oxy-2-[(E)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[2-[(5Z,7Z,9Z,11Z,13Z)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-tridecanoyloxypropyl] (5Z,7Z,9Z,11Z,13Z)-hexadeca-5,7,9,11,13-pentaenoate

C48H72O6 (744.5328612000001)

[3-[(6Z,9Z)-dodeca-6,9-dienoyl]oxy-2-[(6Z,9Z,12Z)-pentadeca-6,9,12-trienoyl]oxypropyl] (7Z,9Z,11Z,13Z,15Z)-octadeca-7,9,11,13,15-pentaenoate

C48H72O6 (744.5328612000001)

[3-[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxy-2-[(7Z,9Z,11Z,13Z)-hexadeca-7,9,11,13-tetraenoyl]oxypropyl] (8Z,11Z,14Z)-heptadeca-8,11,14-trienoate

C48H72O6 (744.5328612000001)

[2-[(9Z,12Z)-pentadeca-9,12-dienoyl]oxy-3-[(5Z,8Z,11Z)-tetradeca-5,8,11-trienoyl]oxypropyl] (5Z,7Z,9Z,11Z,13Z)-hexadeca-5,7,9,11,13-pentaenoate

C48H72O6 (744.5328612000001)

[3-[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxy-2-[(5Z,7Z,9Z,11Z,13Z)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropyl] (11Z,14Z)-heptadeca-11,14-dienoate

C48H72O6 (744.5328612000001)

[1-[(5Z,7Z,9Z,11Z,13Z)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(Z)-tridec-8-enoyl]oxypropan-2-yl] (7Z,9Z,11Z,13Z)-hexadeca-7,9,11,13-tetraenoate

C48H72O6 (744.5328612000001)

[3-[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxy-2-[(5Z,8Z,11Z)-tetradeca-5,8,11-trienoyl]oxypropyl] (7Z,10Z,13Z,16Z)-nonadeca-7,10,13,16-tetraenoate

C48H72O6 (744.5328612000001)

[2-[(6Z,9Z,12Z)-pentadeca-6,9,12-trienoyl]oxy-3-[(7Z,9Z)-tetradeca-7,9-dienoyl]oxypropyl] (5Z,7Z,9Z,11Z,13Z)-hexadeca-5,7,9,11,13-pentaenoate

C48H72O6 (744.5328612000001)

2,3-bis[[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxy]propyl (9Z,11Z,13Z,15Z)-henicosa-9,11,13,15-tetraenoate

C48H72O6 (744.5328612000001)

[3-[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxy-2-[(9Z,12Z)-pentadeca-9,12-dienoyl]oxypropyl] (7Z,9Z,11Z,13Z,15Z)-octadeca-7,9,11,13,15-pentaenoate

C48H72O6 (744.5328612000001)

[3-[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxy-2-[(7Z,9Z)-tetradeca-7,9-dienoyl]oxypropyl] (4Z,7Z,10Z,13Z,16Z)-nonadeca-4,7,10,13,16-pentaenoate

C48H72O6 (744.5328612000001)

[3-[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxy-2-[(Z)-tridec-8-enoyl]oxypropyl] (7Z,9E,11Z,13Z,15Z,17Z)-icosa-7,9,11,13,15,17-hexaenoate

C48H72O6 (744.5328612000001)

[3-[(6Z,9Z)-dodeca-6,9-dienoyl]oxy-2-[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxypropyl] (9Z,11Z,13Z,15Z,17Z)-henicosa-9,11,13,15,17-pentaenoate

C48H72O6 (744.5328612000001)

[3-[(6Z,9Z)-dodeca-6,9-dienoyl]oxy-2-[(5Z,8Z,11Z)-tetradeca-5,8,11-trienoyl]oxypropyl] (4Z,7Z,10Z,13Z,16Z)-nonadeca-4,7,10,13,16-pentaenoate

C48H72O6 (744.5328612000001)

[3-[(6Z,9Z)-dodeca-6,9-dienoyl]oxy-2-[(5Z,7Z,9Z,11Z,13Z)-hexadeca-5,7,9,11,13-pentaenoyl]oxypropyl] (8Z,11Z,14Z)-heptadeca-8,11,14-trienoate

C48H72O6 (744.5328612000001)

[2-[(6Z,9Z,12Z)-pentadeca-6,9,12-trienoyl]oxy-3-[(5Z,8Z,11Z)-tetradeca-5,8,11-trienoyl]oxypropyl] (7Z,9Z,11Z,13Z)-hexadeca-7,9,11,13-tetraenoate

C48H72O6 (744.5328612000001)

[3-[(3Z,6Z,9Z)-dodeca-3,6,9-trienoyl]oxy-2-[(6Z,9Z,12Z)-pentadeca-6,9,12-trienoyl]oxypropyl] (9Z,11Z,13Z,15Z)-octadeca-9,11,13,15-tetraenoate

C48H72O6 (744.5328612000001)

2-[hydroxy-[2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxy-3-pentadecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-hexadec-9-enoyl]oxypropyl] (9E,11E)-octadeca-9,11-dienoate

C40H73O10P (744.4941087999999)

2-[hydroxy-[(2R)-3-[(E)-octadec-6-enoyl]oxy-2-[(E)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[[(2R)-2-[(E)-heptadec-9-enoyl]oxy-3-[(E)-hexadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[[(2R)-3-[(E)-heptadec-9-enoyl]oxy-2-[(E)-hexadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(9E,12E)-heptadeca-9,12-dienoyl]oxypropan-2-yl] (E)-heptadec-9-enoate

C40H73O10P (744.4941087999999)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-hexadec-7-enoyl]oxypropyl] (6E,9E)-octadeca-6,9-dienoate

C40H73O10P (744.4941087999999)

[(2R)-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C43H69O8P (744.4729804)

2-[[(2R)-2-[(E)-heptadec-9-enoyl]oxy-3-[(E)-hexadec-7-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-2-[(9E,11E)-octadeca-9,11-dienoyl]oxy-3-pentadecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-2-[(7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate

C43H69O8P (744.4729804)

[3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(4E,7E)-hexadeca-4,7-dienoyl]oxypropyl] (E)-octadec-11-enoate

C40H73O10P (744.4941087999999)

2-[hydroxy-[(2R)-2-[(2E,4E)-octadeca-2,4-dienoyl]oxy-3-pentadecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-2-[(9E,12E)-octadeca-9,12-dienoyl]oxy-3-pentadecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-hexadec-7-enoyl]oxypropyl] (2E,4E)-octadeca-2,4-dienoate

C40H73O10P (744.4941087999999)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-hexadec-9-enoyl]oxypropan-2-yl] (6E,9E)-octadeca-6,9-dienoate

C40H73O10P (744.4941087999999)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-hexadec-7-enoyl]oxypropan-2-yl] (2E,4E)-octadeca-2,4-dienoate

C40H73O10P (744.4941087999999)

[(2R)-1-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-phosphonooxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate

C43H69O8P (744.4729804)

[(2R)-1-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-phosphonooxypropan-2-yl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C43H69O8P (744.4729804)

[(2R)-2-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C43H69O8P (744.4729804)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (5E,8E)-icosa-5,8-dienoate

C40H73O10P (744.4941087999999)

2-[hydroxy-[(2S)-3-[(11E,14E)-icosa-11,14-dienoyl]oxy-2-tridecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (10E,12E)-octadeca-10,12-dienoate

C43H68O10 (744.4812228000001)

[(2R)-2-[(7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C43H69O8P (744.4729804)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-hexadec-9-enoyl]oxypropyl] (2E,4E)-octadeca-2,4-dienoate

C40H73O10P (744.4941087999999)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-hexadec-7-enoyl]oxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate

C40H73O10P (744.4941087999999)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-hexadec-7-enoyl]oxypropyl] (9E,12E)-octadeca-9,12-dienoate

C40H73O10P (744.4941087999999)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C40H73O10P (744.4941087999999)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-hexadec-7-enoyl]oxypropyl] (9E,11E)-octadeca-9,11-dienoate

C40H73O10P (744.4941087999999)

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-tetradecanoyloxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate

C40H73O10P (744.4941087999999)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxypropyl] (E)-heptadec-9-enoate

C40H73O10P (744.4941087999999)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-hexadec-9-enoyl]oxypropan-2-yl] (2E,4E)-octadeca-2,4-dienoate

C40H73O10P (744.4941087999999)

2-[[3-heptadecanoyloxy-2-[(4E,7E)-hexadeca-4,7-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-hexadec-9-enoyl]oxypropyl] (6E,9E)-octadeca-6,9-dienoate

C40H73O10P (744.4941087999999)

2-[hydroxy-[(2R)-2-[(E)-octadec-7-enoyl]oxy-3-[(E)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-3-octadec-17-enoyloxy-2-[(E)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-phosphonooxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate

C43H69O8P (744.4729804)

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-phosphonooxypropyl] (6E,9E,12E,15E,18E)-tetracosa-6,9,12,15,18-pentaenoate

C43H69O8P (744.4729804)

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-phosphonooxypropyl] (6E,9E,12E,15E,18E,21E)-tetracosa-6,9,12,15,18,21-hexaenoate

C43H69O8P (744.4729804)

[(2R)-1-[(9E,12E)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropan-2-yl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C43H69O8P (744.4729804)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-hexadec-7-enoyl]oxypropan-2-yl] (9E,11E)-octadeca-9,11-dienoate

C40H73O10P (744.4941087999999)

[(2R)-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C43H69O8P (744.4729804)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-hexadecanoyloxypropyl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C40H73O10P (744.4941087999999)

[(2R)-1-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate

C43H69O8P (744.4729804)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (9E,12E,15E)-octadeca-9,12,15-trienoate

C40H73O10P (744.4941087999999)

[(2R)-2-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C43H69O8P (744.4729804)

[(2R)-2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-phosphonooxypropyl] (8E,11E,14E)-icosa-8,11,14-trienoate

C43H69O8P (744.4729804)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-hexadecanoyloxypropan-2-yl] (6E,9E,12E)-octadeca-6,9,12-trienoate

C40H73O10P (744.4941087999999)

2-[hydroxy-[(2R)-3-[(6E,9E)-octadeca-6,9-dienoyl]oxy-2-pentadecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-tetradec-9-enoyl]oxypropan-2-yl] (11E,14E)-icosa-11,14-dienoate

C40H73O10P (744.4941087999999)

2-[hydroxy-[(2R)-2-[(E)-octadec-4-enoyl]oxy-3-[(E)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-2-[(E)-octadec-9-enoyl]oxy-3-[(E)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate

C40H73O10P (744.4941087999999)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-hexadec-7-enoyl]oxypropan-2-yl] (6E,9E)-octadeca-6,9-dienoate

C40H73O10P (744.4941087999999)

[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-phosphonooxypropyl] (15E,18E,21E)-tetracosa-15,18,21-trienoate

C43H69O8P (744.4729804)

2-[hydroxy-[(2R)-3-[(E)-octadec-13-enoyl]oxy-2-[(E)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[2-[(4Z,7Z)-octadeca-4,7-dienoyl]oxy-3-pentadecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-2-[(6E,9E)-octadeca-6,9-dienoyl]oxy-3-pentadecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-1-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate

C43H69O8P (744.4729804)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-hexadec-9-enoyl]oxypropan-2-yl] (9E,12E)-octadeca-9,12-dienoate

C40H73O10P (744.4941087999999)

[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate

C43H68O10 (744.4812228000001)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-[(E)-hexadec-9-enoyl]oxypropan-2-yl] (9E,11E)-octadeca-9,11-dienoate

C40H73O10P (744.4941087999999)

2-[hydroxy-[(2R)-3-[(2E,4E)-octadeca-2,4-dienoyl]oxy-2-pentadecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-2-[(11E,14E)-icosa-11,14-dienoyl]oxy-3-tridecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-1-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E)-icosa-5,8,11-trienoate

C43H69O8P (744.4729804)

[(2R)-2-[(6E,9E)-octadeca-6,9-dienoyl]oxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C43H69O8P (744.4729804)

[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoate

C43H68O10 (744.4812228000001)

[(2R)-1-[(9E,11E)-octadeca-9,11-dienoyl]oxy-3-phosphonooxypropan-2-yl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C43H69O8P (744.4729804)

2-[hydroxy-[(2R)-2-[(E)-octadec-11-enoyl]oxy-3-[(E)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-3-[(E)-octadec-11-enoyl]oxy-2-[(E)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(2S,5S,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypropyl] (11E,13E,15E)-octadeca-11,13,15-trienoate

C43H68O10 (744.4812228000001)

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (11E,14E)-icosa-11,14-dienoate

C40H73O10P (744.4941087999999)

2-[hydroxy-[(2R)-2-octadec-17-enoyloxy-3-[(E)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-tetradec-9-enoyl]oxypropyl] (5E,8E)-icosa-5,8-dienoate

C40H73O10P (744.4941087999999)

2-[[(2R)-3-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-2-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-2-[(E)-octadec-6-enoyl]oxy-3-[(E)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-1-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-3-tetradecanoyloxypropan-2-yl] (8E,11E,14E)-icosa-8,11,14-trienoate

C40H73O10P (744.4941087999999)

[3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxypropyl] octadecanoate

C40H73O10P (744.4941087999999)

2-[hydroxy-[(2R)-3-[(E)-octadec-4-enoyl]oxy-2-[(E)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-3-[(9E,12E)-octadeca-9,12-dienoyl]oxy-2-pentadecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-2-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C43H69O8P (744.4729804)

[(2S)-3-[[(2R)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-tetradecanoyloxypropyl] (5E,8E,11E)-icosa-5,8,11-trienoate

C40H73O10P (744.4941087999999)

[(2R)-3-[[(2S)-2,3-dihydroxypropoxy]-hydroxyphosphoryl]oxy-2-[(E)-hexadec-9-enoyl]oxypropyl] (9E,12E)-octadeca-9,12-dienoate

C40H73O10P (744.4941087999999)

2-[hydroxy-[(2R)-3-[(E)-octadec-7-enoyl]oxy-2-[(E)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-1-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-phosphonooxypropan-2-yl] (4E,7E,10E,13E,16E)-docosa-4,7,10,13,16-pentaenoate

C43H69O8P (744.4729804)

[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-phosphonooxypropyl] (9E,12E,15E,18E)-tetracosa-9,12,15,18-tetraenoate

C43H69O8P (744.4729804)

2-[[(2R)-3-[(E)-heptadec-9-enoyl]oxy-2-[(E)-hexadec-7-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-1-[(7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoyl]oxy-3-phosphonooxypropan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate

C43H69O8P (744.4729804)

2-[[(2R)-2-[(13E,16E)-docosa-13,16-dienoyl]oxy-3-undecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-2-[(6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate

C43H69O8P (744.4729804)

[(2R)-2-[(9E,12E)-octadeca-9,12-dienoyl]oxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C43H69O8P (744.4729804)

[(2R)-2-[(9E,11E)-octadeca-9,11-dienoyl]oxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C43H69O8P (744.4729804)

[(2R)-1-[(6E,9E)-octadeca-6,9-dienoyl]oxy-3-phosphonooxypropan-2-yl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C43H69O8P (744.4729804)

2-[hydroxy-[(2R)-2-[(5E,8E)-icosa-5,8-dienoyl]oxy-3-tridecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[(2R)-3-[(9E,11E)-octadeca-9,11-dienoyl]oxy-2-pentadecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-1-[(6E,9E,12E)-octadeca-6,9,12-trienoyl]oxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C43H69O8P (744.4729804)

[(2R)-2-[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy-3-phosphonooxypropyl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate

C43H69O8P (744.4729804)

[(2R)-1-[(2E,4E)-octadeca-2,4-dienoyl]oxy-3-phosphonooxypropan-2-yl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C43H69O8P (744.4729804)

2-[[(2S)-3-[(13E,16E)-docosa-13,16-dienoyl]oxy-2-undecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-2-[(2E,4E)-octadeca-2,4-dienoyl]oxy-3-phosphonooxypropyl] (4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoate

C43H69O8P (744.4729804)

2-[hydroxy-[(2R)-2-[(E)-octadec-13-enoyl]oxy-3-[(E)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

[(2R)-1-[(9E,12E,15E)-octadeca-9,12,15-trienoyl]oxy-3-phosphonooxypropan-2-yl] (7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoate

C43H69O8P (744.4729804)

2-[hydroxy-[(2S)-3-[(5E,8E)-icosa-5,8-dienoyl]oxy-2-tridecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[[(2R)-2-[(9E,12E)-heptadeca-9,12-dienoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[[2-[(Z)-heptadec-9-enoyl]oxy-3-[(Z)-hexadec-9-enoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[[3-heptadecanoyloxy-2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[[3-dodecanoyloxy-2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[2-[(Z)-icos-11-enoyl]oxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[2-[(Z)-octadec-9-enoyl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[3-nonanoyloxy-2-[(13Z,16Z)-tetracosa-13,16-dienoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-tridecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[[3-heptanoyloxy-2-[(15Z,18Z)-hexacosa-15,18-dienoyl]oxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxy-3-tetradecanoyloxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[[2-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-3-undecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[hydroxy-[2-[(Z)-nonadec-9-enoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]phosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-hexadecanoyloxypropoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

C41H79NO8P+ (744.5543004)

2-[carboxy-[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]methoxy]ethyl-trimethylazanium

C44H74NO8+ (744.5414144)

2-[carboxy-[3-[(Z)-hexadec-9-enoyl]oxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropoxy]methoxy]ethyl-trimethylazanium

C44H74NO8+ (744.5414144)

2-[carboxy-[2-[(8Z,11Z,14Z,17Z,20Z,23Z)-hexacosa-8,11,14,17,20,23-hexaenoyl]oxy-3-octanoyloxypropoxy]methoxy]ethyl-trimethylazanium

C44H74NO8+ (744.5414144)

2-[carboxy-[2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-dodecanoyloxypropoxy]methoxy]ethyl-trimethylazanium

C44H74NO8+ (744.5414144)

2-[carboxy-[3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]methoxy]ethyl-trimethylazanium

C44H74NO8+ (744.5414144)

2-[carboxy-[3-decanoyloxy-2-[(6Z,9Z,12Z,15Z,18Z,21Z)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxypropoxy]methoxy]ethyl-trimethylazanium

C44H74NO8+ (744.5414144)

2-[carboxy-[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]methoxy]ethyl-trimethylazanium

C44H74NO8+ (744.5414144)

2-[carboxy-[3-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropoxy]methoxy]ethyl-trimethylazanium

C44H74NO8+ (744.5414144)

PG(18:3(6Z,9Z,12Z)/16:0)

C40H73O10P (744.4941087999999)

monogalactosyldiacylglycerol 34:7

C43H68O10 (744.4812228000001)

phosphatidylglycerol 34:3

C40H73O10P (744.4941087999999)

A phosphatidylglycerol in which the two acyl groups contain 34 carbon atoms and 3 double bonds.

phosphatidylglycerol (18:3/16:0)

C40H73O10P (744.4941087999999)

A phosphatidylglycerol 34:3 in which the 1- and 2-acyl groups are specified as octadecatrienoyl and hexadecanoyl respectively.

1,2-diarachidonoyl-sn-glycero-3-phosphate

C43H69O8P (744.4729804)

A 1-acyl-2-arachidonoyl-sn-glycero-3-phosphate in which the 1-acyl group is also arachidonoyl.

1-alpha-linolenoyl-2-hexadecanoylphosphatidylglycerol

C40H73O10P (744.4941087999999)

A phosphatidylglycerol (18:3/16:0) in which the 1- and 2-acyl groups are specified as alpha-linolenoyl and hexadecanoyl respectoively.

1-oleoyl-2-[(4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl]-sn-glycero-3-phosphate(2-)

C43H69O8P (744.4729804)

A 1,2-diacyl-sn-glycerol 3-phosphate(2-) in which the 1- and 2-acyl substituent are specified as oleoyl and (4Z,7Z,10Z,13Z,16Z,19Z)-docosahexaenoyl respectively; major species at pH 7.3.

TG(45:10)

C48H72O6 (744.5328612000001)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

LBPA(34:3)

C40H73O10P (744.4941087999999)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

MGDG O-34:8;O

C43H68O10 (744.4812228000001)

MGDG O-35:7

C44H72O9 (744.5176062)

DGGA 31:1;O

C40H72O12 (744.5023512)

DGGA 32:0

C41H76O11 (744.5387346)

MGGA 34:7

C43H68O10 (744.4812228000001)

PA O-18:0/20:3;O2

C41H77O9P (744.5304922)

PA O-38:3;O2

C41H77O9P (744.5304922)

PA O-40:9;O

C43H69O8P (744.4729804)

PA P-18:1/22:7;O

C43H69O8P (744.4729804)

PA P-20:0/18:2;O2

C41H77O9P (744.5304922)

PA P-20:1/18:1;O2

C41H77O9P (744.5304922)

PA 18:0/20:2;O

C41H77O9P (744.5304922)

PA 20:0/18:2;O

C41H77O9P (744.5304922)

PA 20:1/18:1;O

C41H77O9P (744.5304922)

PA 38:2;O

C41H77O9P (744.5304922)

PA 18:2_22:6

C43H69O8P (744.4729804)

PA 18:3_22:5

C43H69O8P (744.4729804)

PA 18:4_22:4

C43H69O8P (744.4729804)

PA 20:3_20:5

C43H69O8P (744.4729804)

PA 20:4/20:4

C43H69O8P (744.4729804)

BMP 34:3

C40H73O10P (744.4941087999999)

PG O-11:0/24:3

C41H77O9P (744.5304922)

PG O-18:1/17:2

C41H77O9P (744.5304922)

PG O-18:2/17:1

C41H77O9P (744.5304922)

PG O-20:2/15:1

C41H77O9P (744.5304922)

PG O-34:4;O

C40H73O10P (744.4941087999999)

PG P-16:0/18:3;O

C40H73O10P (744.4941087999999)

PG P-16:1/18:2;O

C40H73O10P (744.4941087999999)

PG P-18:0/17:2

C41H77O9P (744.5304922)

PG P-18:0/17:2 or PG O-18:1/17:2

C41H77O9P (744.5304922)

PG P-18:1/17:1

C41H77O9P (744.5304922)

PG P-18:1/17:1 or PG O-18:2/17:1

C41H77O9P (744.5304922)

PG P-20:1/15:1

C41H77O9P (744.5304922)

PG P-20:1/15:1 or PG O-20:2/15:1

C41H77O9P (744.5304922)

PG P-35:2

C41H77O9P (744.5304922)

PG P-35:2 or PG O-35:3

C41H77O9P (744.5304922)

PG 14:0_20:3

C40H73O10P (744.4941087999999)

PG 14:1_20:2

C40H73O10P (744.4941087999999)

PG 16:0_18:3

C40H73O10P (744.4941087999999)

PG 16:1_18:2

C40H73O10P (744.4941087999999)

PG 17:1_17:2

C40H73O10P (744.4941087999999)

PEth 36:2;O

C41H77O9P (744.5304922)

PEth 38:8

C43H69O8P (744.4729804)

PM 37:2;O

C41H77O9P (744.5304922)

PM 39:8

C43H69O8P (744.4729804)

CerPE 19:2;O2/22:6

C43H73N2O6P (744.5205968)

CerPE 41:8;O2

C43H73N2O6P (744.5205968)

SM 16:2;O2/22:6

C43H73N2O6P (744.5205968)

SM 38:8;O2

C43H73N2O6P (744.5205968)

BisMePA(38:8)

C43H69O8P (744.4729804)

Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

(2s,3s,4r,5r,6s)-2-{[(3s,4e,6e,8e,10e,12e,14e,16e,18e,20e,22e,24e)-2-hydroxy-25-[(4r)-4-hydroxy-2,6,6-trimethylcyclohex-1-en-1-yl]-2,6,10,14,19,23-hexamethylpentacosa-4,6,8,10,12,14,16,18,20,22,24-undecaen-3-yl]oxy}-4-methoxy-6-methyloxane-3,5-diol

C47H68O7 (744.4964778000001)

2-{[2-hydroxy-25-(4-hydroxy-2,6,6-trimethylcyclohex-1-en-1-yl)-2,6,10,14,19,23-hexamethylpentacosa-4,6,8,10,12,14,16,18,20,22,24-undecaen-3-yl]oxy}-4-methoxy-6-methyloxane-3,5-diol

C47H68O7 (744.4964778000001)

[3,4,5-tris(acetyloxy)-6-{[1-(5-ethyl-6-methylheptan-2-yl)-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}oxan-2-yl]methyl acetate

C43H68O10 (744.4812228000001)

{4-carbamimidamido-1-[(1-{[1-({1-[(1,3-dicarboxypropyl)(methyl)carbamoyl]-3-hydroxy-4-(n'-methylcarbamimidamido)butyl}-c-hydroxycarbonimidoyl)-2-methylpropyl]-c-hydroxycarbonimidoyl}-2-methylpropyl)-c-hydroxycarbonimidoyl]butyl}trimethylazanium

[C32H62N11O9]+ (744.4731742)

(3s,3as,5r,5ar,6r,7r,9r,9ar)-5-{[(2r,3r)-2-hydroxy-3-methylpentanoyl]oxy}-7-(2-hydroxypropan-2-yl)-6-(3-methoxy-3-oxopropyl)-3a,6,9a-trimethyl-3-[(3s,5s)-5-(2-methylprop-1-en-1-yl)oxolan-3-yl]-2h,3h,4h,5h,5ah,7h,8h,9h-cyclopenta[a]naphthalen-9-yl (2r,3e)-2-hydroxy-3-methylpent-3-enoate

C43H68O10 (744.4812228000001)

[(2r,3r,4s,5r,6r)-6-{[(1r,3as,3bs,7s,9ar,9bs,11ar)-1-[(2r,5r)-5-ethyl-6-methylheptan-2-yl]-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-7-yl]oxy}-3,4,5-tris(acetyloxy)oxan-2-yl]methyl acetate

C43H68O10 (744.4812228000001)

(3r)-2-[(1r,3as,5ar,7r,8s,9ar,11ar)-3a,7,8-trihydroxy-9a,11a-dimethyl-5-oxo-1h,2h,3h,5ah,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-3,6-dihydroxy-6-methylheptan-3-yl (9z)-octadec-9-enoate

C45H76O8 (744.5539896)